Pathology software company Aiosyn and Pramana, a company supplying automated digital pathology solutions, have announced a collaboration to deliver inline detection of kidney structures in histology whole-slide images (WSIs).
Leveraging the industry's first and only digital pathology scanners with integrated Edge AI computing technology from Pramana, Aiosyn’s NephroPath platform streamlines renal biopsy and resection assessments.
Technology integration between Aiosyn and Pramana enables the analysis of digital pathology scans as soon as the scanner begins image acquisition. Aiosyn’s AI analysis runs within the edge compute infrastructure that’s integrated to the Pramana digital scanners and starts before the full slide scan is completed. As opposed to existing solutions that depend solely on cloud-hosted AI analysis of fully scanned whole slide images, this collaboration not only accelerates workflows but also strengthens data privacy and security by minimising the need for transferring large WSI files to external systems.
“Aiosyn has achieved a groundbreaking milestone by integrating our NephroPath platform with Pramana’s unique scanning technology,” said David Tellez, CTO of Aiosyn. “With Edge AI computing, we enable real-time tissue structure detection, eliminating delays and privacy concerns. It's a big step toward seamless AI integration in pathology, enhancing diagnostic precision and efficiency.”
Through the NephroPath platform (pictured), Aiosyn’s AI algorithms offer an automated assessment of kidney tissue, identifying and quantifying key structures such as healthy and sclerotic glomeruli, tubuli, arteries, capsule, and the interstitium. Since NephroPath AI analyses the sample as it is scanned, Pramana’s system can acquire the image at multiple focal planes for each glomerulus, tubule, and other structures. Pathologists are not only able to access the detections of the AI model but also browse through the digital z-stack. The NephroPath platform is currently designated for Research Use Only.
“Edge AI compute is opening possibilities for a future generation of digital pathology, where Pramana pioneered the concept of autonomous scanning with built-in quality assurance,” said Prasanth Perugupalli, Chief Product Officer at Pramana. “Our partnerships with leading AI solution providers like Aiosyn offer industry-leading solutions to unique problems that were simply not possible to tackle before.”
Moving forward, Aiosyn and Pramana plan to expand their capabilities by integrating the detection and quantification of additional tissue structures. This joint solution will be showcased at USCAP 2025 in Boston, Mass., held 22-27 March.